pirenzepine has been researched along with selegiline in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Axe, FU; Bembenek, SD; Butler, CR; Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Karlsson, L; Lundeen, K; Riley, JP; Savall, BM; Tays, KL; Wei, J; Williams, KN; Xue, X | 1 |
| Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
| Ghaemi, M; Rudolf, J; Schmülling, S | 1 |
| Marsh, C; Preskorn, SH; Shad, MU | 1 |
6 other study(ies) available for pirenzepine and selegiline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Catalysis; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship | 2008 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Olanzapine; Paranoid Disorders; Parkinson Disease; Piperidines; Pirenzepine; Selegiline; Severity of Illness Index | 1999 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Haloperidol; Health Care Costs; Humans; Olanzapine; Parkinson Disease; Pirenzepine; Selegiline; Trihexyphenidyl | 2001 |